The ESCGT 30th Annual Congress was once again filled with the pioneering research and idea sharing that are poised to shape the future of cell and gene therapy. Here are just a couple of the takeaways that had special resonance for our team at Cellistic:
One of the challenges garnering substantial attention at this year’s event was pursuit of regulatory approvals for iPSC-based therapies. The central question that emerged: "How do we intend to address karyotype quality and residual progenitor populations for platforms?" This critical inquiry touches upon the very core of safety and efficacy in iPSC-based therapies. While certain regulatory questions are still unanswered, the unwavering commitment of the cell and gene therapy community to deliver safe, efficient, and high-quality therapies to patients remains strong.
ESCGT 2023 introduced us to some of the most exciting scientific developments and innovations that are propelling the field of cell and gene therapy forward. Among them:
While scientific discussions and poster presentations help set the conference tone, the moments of camaraderie and fun generated lasting memories, too. The Molecular Mingle, in particular, provided an ideal backdrop for us to connect with old and new friends in a relaxed, social setting. (The photo booth stole the spotlight, capturing both dozens of team pix and the true vibrancy and enthusiasm of the conference.)
Next year's ESGCT annual congress will be in Rome, but between now and then, our team from Cellistic will be capitalizing on opportunities around the world to learn from our scientific peers and present our own original research. Based on what we heard in Brussels and what we know is happening in our labs, there's good reason to be optimistic about the future of cell and gene therapy. See you at the next conference!